Abstract
Prostatic glandular epithelial cells undergo apoptosis in response to androgen-deprivation. The molecular determinants of androgen-responsiveness in these cells are incompletely understood. Recent evidence suggests that bcl-2 gene family members may be important in this context. We used the probasin promoter to target a human bcl-2 transgene specifically to the prostate in order to assess its impact on conferring resistance to androgen withdrawal in, otherwise sensitive, prostatic glandular epithelial cells in vivo. We examined the contribution of bax to mediating androgen-responsiveness in prostatic glandular epithelial cells using bax knockout mice. The histologic appearance of the prostates from probasin-bcl-2 transgenic mice or bax−/− mice did not differ from those of control littermates. There was no evidence of hyperplastic or neoplastic growth. There was no difference between probasin bcl-2 transgenic mice, bax−/− mice, and control littermates in steady-state levels of apoptosis. Following castration our findings suggest that both bax and bcl-2 may each contribute to the androgen-responsiveness of prostatic glandular epithelial cells. It is apparent from these results, however, that bax is not required to mediate cell death in prostatic glandular epithelial cells following castration. A comparison between the apoptotic indices in the ventral prostate from the probasin-bcl-2 and bax−/− mice following castration suggests that the presence of bcl-2 may be a more important indicator of androgen-sensitivity than a deficiency of bax.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Boghaert ER, Sells SF, Walid AJ, Malone P, Williams NM, Weinstein MH, Strange R and Rangnekar VM . 1997 Cell Growth Differ 8: 881–890
Banerjee PP, Banerjee S, Tilly KI, Tilly JL, Brown TR and Zirkin BR . 1995 Endocrinology 136: 4368–4376
Beham AW, Sarkiss M, Brisbay S, Tu SM, von Eschenbach AC and McDonnell TJ . 1998 Int J Mol Med 1: 953–959
Bruckheimer EM, Gjertsen BT and McDonnell TJ . 1999 Semin Oncol 26: 382–398
English HF, Samtem RJ and Isaacs JT . 1987 Prostate 11: 229–242
Cleutjens KB, van der Korput HA, Ehren-van Eekelen CC, Sikes RA, Fasciana C, Chung LW and Trapman J . 1997 Mol Endocrinol 11: 1256–1265
Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S and Buttyan R . 1993 Am J Pathol 143: 390–400
Gavrieli Y, Sherman Y and Ben-Sasson SA . 1992 J Cell Biol 119: 493–501
Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM and Greenberg NM . 1996 Cancer Res 56: 4096–4102
Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ and Greenberg NM . 1997 Cancer Res 57: 4687–4691
Greenberg NM, DeMayo FJ, Sheppard PC, Barrios R, Lebovitz R, Finegold M, Angelopoulou R, Dodd JG, Duckworth ML and Rosen JM . 1994 Mol Endocrinol 8: 230–239
Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, Cunha GR, Donjacour AA, Matusik RJ and Rosen JM . 1995 Proc Natl Acad Sci USA 92: 3439–3443
Gross A, McDonnell JM and Korsmeyer SJ . 1999 Genes Dev 13: 1899–1911
Hockenbery DM, Zutter M, Hickey W, Nahm M and Korsmeyer SJ . 1991 Proc Natl Acad Sci USA 88: 6961–6965
Knudson CM, Tung KS, Tourtellotte WG, Brown GA and Korsmeyer SJ . 1995 Science 270: 96–99
Knudson CM and Korsmeyer SJ . 1997 Nat Genet 16: 358–363
Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE and Oltvai ZN . 1993 Semin Cancer Biol 4: 327–332
Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S and Reed JC . 1996 Am J Pathol 148: 1567–1576
Lakins J, Bennett SA, Chen JH, Arnold JM, Morrissey C, Wong P, O'Sullivan J and Tenniswood M . 1998 J Biol Chem 273: 27887–27895
Maroulakou IG, Anver M, Garret L and Green JE . 1994 Proc Natl Acad Sci USA 91: 11236–11240
Martinou JC, Dubois-Dauphin M, Staple JK, Rodriguez I, Frankowksi H, Missotten M, Albertini P, Talabot D, Catsicas S and Pietra C . 1994 Neuron 13: 1017–1030
McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP and Korsmeyer SJ . 1989 Cell 57: 79–88
McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM and Campbell ML . 1992 Cancer Res 52: 6940–6944
Oltvai ZN, Milliman CL and Korsmeyer SJ . 1993 Cell 74: 609–619
Pang S, Dannull J, Kaboo R, Xie Y, Tso CL, Michel K, deKernion JB and Belldegrun AS . 1997 Cancer Res 57: 495–499
Perlman H, Zhang X, Chen MW, Walsh K and Buttyan R . 1999 Cell Death Diff 6: 48–54
Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS and Buttyan R . 1995 Cancer Res 55: 4438–4445
Schorr K, Li M, Bar-Peled U, Lewis A, Heredia A, Lewis B, Knudson CM, Korsmeyer SJ, Jager R, Weiher H and Furth PA . 1999 Cancer Res 59: 2541–2545
Tunn S, Nass R, Ekkernkamp A, Schulze H and Krieg M . 1989 Prostate 15: 263–271
Westin P, Lo P, Marin MC, Fernandez A, Sarkiss M, Tu SM, Brisbay SM, von Eschenbach AC and McDonnell TJ . 1997 Int J Oncol 10: 113–118
Zhang X, Chen MW, Ng A, Ng PY, Lee C, Rubin M, Olsson CA and Buttyan R . 1997 Prostate 32: 16–26
Acknowledgements
This work was supported by a grant from the American Cancer Society (RPG-96-036-04-CDD), an award from CaP CURE (The Association for the Cure of Cancer of the Prostate), and NIH Training Grant T32 CA67759-01 (EMB).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bruckheimer, E., Cho, S., Brisbay, S. et al. The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo. Oncogene 19, 2404–2412 (2000). https://doi.org/10.1038/sj.onc.1203571
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203571
Keywords
This article is cited by
-
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses
Nature Communications (2018)
-
Molecular mediators of cell death in multistep carcinogenesis: a path to targeted therapy
Cell Death & Differentiation (2006)
-
Abnormalities of apoptotic and cell cycle regulatory proteins in distinct histopathologic components of benign prostatic hyperplasia
Prostate Cancer and Prostatic Diseases (2004)
-
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
Nature Medicine (2004)
-
Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill
Prostate Cancer and Prostatic Diseases (2003)